In thyroid eye disease, specific molecules related to immune signaling and oxidative stress in the blood and tears change with disease severity, suggesting they could one day be used to track how well treatments are working.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether specific metabolites in serum or tears reliably distinguish active from inactive thyroid eye disease across multiple studies.
A systematic review and meta-analysis of 15+ studies measuring tryptophan metabolites (kynurenine, quinolinic acid), oxidative stress markers (8-OHdG, MDA), and inflammatory cytokines in serum and tear fluid of TED patients, comparing active vs. inactive disease states, with standardized metabolomic platforms.
Whether changes in tear or serum metabolites predict or correlate with clinical response to teprotumumab in thyroid eye disease.
A prospective RCT of 150 patients with active TED, measuring serum and tear metabolites (kynurenine, NAD+, MDA) at baseline, 6, and 12 weeks during teprotumumab treatment, with primary outcome of correlation between metabolite change and clinical response (Clinical Activity Score reduction ≥3 points).
Whether baseline metabolite profiles predict progression or relapse of thyroid eye disease after treatment.
A prospective cohort study of 300 TED patients treated with immunosuppression or teprotumumab, with serial metabolomic profiling (serum and tear) at 0, 3, 6, and 12 months, and 2-year follow-up for relapse or progression.
The difference in metabolite profiles between active and inactive thyroid eye disease.
A cross-sectional study comparing serum and tear metabolites in 120 patients with active TED (CAS ≥3) and 120 with inactive TED (CAS ≤1), matched for age, sex, and disease duration, using standardized LC-MS.
Rare cases of dramatic metabolite shifts coinciding with rapid clinical improvement or worsening in TED.
A case series of 10 TED patients with rapid clinical deterioration or improvement during treatment, with paired serum and tear metabolomic profiling before and after change.